Climb Global Solutions Acquires French IT Distributor NeoVAD for Approximately €16 Million

BTIG reiterated a Buy rating on Climb Bio with a $32 price target, implying 263.2% upside from the Oct 26 close. The firm cited positive early trial data for budoprutug and a favorable safety profile for CLYM116, boosting confidence in the company's pipeline.

Climb Bio (NASDAQ: CLYM) reported initial Phase 2 trial results for its kidney-disease treatment, PrisMN, showing 38% immunologic remission in the low-dose cohort and a 70% reduction in disease-linked antibodies. The company plans to release additional data in 2027. Climb shares closed at $10.19 before the announcement. The trial aims to identify a dose for pivotal development, with no serious adverse events reported.

Climb Global Solutions (NASDAQ:CLMB) reported Q2 2026 results for the quarter ended June 30, 2026. Net sales rose 9% to $174.2M and gross billings increased 17% to $587.3M. Gross profit grew 15% to $30.2M. Net income was $5.5M, or $0.30 diluted EPS, vs $6.0M. Adjusted EBITDA was $11.3M. Cash was $56.6M and the company had no debt.

Climb Global Solutions, Inc. (CLMB) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Climb Global Solutions Reports Second Quarter 2026 Results Net Sales up 9% to $174.2 Million; Gross Billings up 17% to $587.3 Million; Gross Profit up 15% to $30.2 Million EATONTOWN, N.J., July 29, 2026 – Climb Global Solutions, Inc. (NASDAQ:CLMB) (“Climb” or the “Co

Guidewire will acquire UK insurtech firm hyperexponential for up to $2.1bn, including $1.7bn upfront and $400m in earn-outs. The deal aims to enhance AI-assisted underwriting, with hyperexponential's software supporting $75bn in annual commercial premiums. Guidewire expects the acquisition to add at least 650 basis points to its fiscal 2027 ARR and 150 basis points from fiscal 2028 onwards, while maintaining margin targets. The deal is set to close in Q2 FY 2027.

NUBURU (BURU) completed a 70% acquisition of TEKNE, entering defense manufacturing. As of June 30, 2026, its stockholders' equity was ~$10.13M, exceeding the NYSE American's $4M threshold. TEKNE reported ~$96.8M in remaining order value, though preliminary. The move marks a strategic shift for NUBURU, aiming for listing compliance and revenue growth.